Health & Research Goals
BPC-157 (Body Protection Compound-157)
BPC-157 (Compuesto de Protección Corporal-157)
BPC-157 is a synthetic pentadecapeptide consisting of 15 amino acids derived from a protective protein found in human gastric juic…
Primary Description
BPC-157 is a synthetic pentadecapeptide consisting of 15 amino acids derived from a protective protein found in human gastric juice. Originally studied for its gastroprotective effects, research has expanded to investigate its potential role in tissue repair, wound healing, and regeneration across multiple organ systems. Despite extensive preclinical research, BPC-157 remains investigational with no approved clinical applications in humans. It is widely self-administered in the biohacker and longevity community based on anecdotal reports of accelerated healing and anti-inflammatory effects.
Key Benefits
- Accelerated healing
- Reduced inflammation
- Gut protection
Notably resistant to enzymatic degradation and stable in gastric acid — a property that supports oral bioavailability research.
Demonstrated Effects
- Accelerated tendon and ligament healing via VEGFR2 angiogenesis
- Gastroprotection and GI mucosal repair
- Muscle injury recovery and reduced recovery time
- Anti-inflammatory effects through cytokine modulation (IL-6, TNF-alpha)
- Neuroprotective effects in TBI and stroke models
- Enhanced wound closure and collagen deposition
- Joint and bone healing support
- Favorable preclinical safety profile with no observed toxicity
Proposed Mechanisms of Action
1. VEGFR2 Pathway Activation (Angiogenesis)
BPC-157 upregulates VEGFR2, stimulating formation of new blood vessels and improving oxygen and nutrient delivery to injured areas.
2. Nitric Oxide (NO) System Modulation
Interacts with the nitric oxide pathway to promote vasodilation, tissue perfusion, and healing via eNOS and nNOS systems.
3. FAK-Paxillin Pathway Activation
Activates focal adhesion kinase (FAK) and paxillin involved in cell migration, proliferation, and wound closure.
4. Cytokine Modulation (Anti-inflammatory)
Modulates pro-inflammatory cytokines including IL-6 and TNF-alpha, normalizing inflammatory signaling without immune suppression.
5. Collagen Synthesis Enhancement
Promotes collagen organization and synthesis, particularly in tendon and ligament tissue.
6. Gastric Cytoprotection
Protects gastric mucosa from damage via COX-2 regulation and prostaglandin involvement — the most extensively studied mechanism.
Research Evidence & Clinical Data
Investigated Applications
Tendon and Ligament Repair
Anecdotal: HighOne of the most commonly reported uses in the community. Users report significant improvement in tendon and ligament injuries — particularly patellar tendon, rotator cuff, and Achilles tendon — within 2–6 weeks of use.
Preclinical basis: VEGFR2 pathway activation promoting angiogenesis and collagen organization.
Gastrointestinal Healing
Anecdotal: HighUsers with conditions such as leaky gut, IBS, gastric ulcers, Crohn's-like symptoms, and NSAID-induced GI damage report significant symptomatic relief. Oral administration is used specifically for GI-targeted effects.
Preclinical basis: Derived from gastric juice protein; gastroprotective effects demonstrated across multiple preclinical ulcer models.
Muscle Injury Recovery
Anecdotal: HighWidely used by athletes after muscle tears, strains, and overuse injuries. Community reports suggest faster return to training and reduced pain markers compared to rest alone.
Preclinical basis: Reduces damage markers and promotes satellite cell activity in muscle injury models.
Neuroprotection and CNS Recovery
Anecdotal: EmergingA growing number of community reports involve use after concussion, traumatic brain injury, or post-surgery cognitive fog. Users describe improved clarity and reduced inflammation-related symptoms.
Preclinical basis: Reduced neuronal damage and improved functional recovery in TBI and stroke models.
Scientific References
- 1.
- 2.
- 3.Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent ReviewPharmaceuticals (Basel)2025
- 4.
- 5.
Safety Profile
Common Side Effects
- Mild injection site redness or tenderness
- Transient headache in first 1–2 weeks
- Occasional mild nausea
- Minimal (injection site reactions)
Contraindications
- Active or prior cancer history (theoretical angiogenesis risk via VEGFR2)
- Pregnancy or breastfeeding
- Pediatric use (under 18)
- Diabetic retinopathy or pathological angiogenesis conditions
- Active malignancy (theoretical)
Legal & Regulatory Status
Not approved in any country. Research chemical / investigational compound. Not a scheduled substance in most jurisdictions but cannot legally be sold for human consumption in the US. WADA prohibited (S0). Schedule 4 in Australia.
No aprobado en ningún país. Químico de investigación / compuesto en investigación. No es sustancia controlada en la mayoría de jurisdicciones pero no puede venderse legalmente para consumo humano en EE.UU. Prohibido por WADA (S0). Categoría 4 en Australia.
Research Protocols
Dosing Protocols
Routes of Administration
subcutaneous
intramuscular
oral
Reconstitution Guide
Pharmacokinetics
| Half-Life | Not well-characterized in humans; preclinical data suggests short half-life requiring daily dosing |
Monitoring & Risk Management
Ongoing Monitoring Steps
- Injection site inspection at every injection — watch for nodules, spreading redness, or pus
- Weekly self-rating of pain scores and range of motion
- Monitor GI symptoms daily during first 2 weeks if using orally
- General wellbeing weekly — energy, sleep, mood
- Skin and soft tissue changes monthly on extended cycles
Critical Warning Signs
- Unexplained lumps or masses — stop immediately, seek evaluation
- Anaphylactic reaction (swelling, breathing difficulty, hives) — emergency
- Severe or persistent nausea/vomiting
- Sudden severe headache
- Significant mood or cognitive changes persisting over 1 week
Featured in Stacking Protocols
Community-researched combinations involving this compound